Seqirus announces Health Canada approval of expanded age indication of its cell-based quadrivalent influenza vaccine for people two years of age and older

Seqirus

18 March 2021 - Seqirus announced that Health Canada has approved Flucelvax Quadrivalent (influenza vaccine), its cell-based quadrivalent influenza vaccine, for an expanded age indication for people two years of age and older. 

Health Canada previously approved Flucelvax Quadrivalent for use in persons nine years of age and older.

Flucelvax Quadrivalent will be available as a 0.5 mL intramuscular vaccine per dose for the 2021/22 Canadian influenza season.

Read Seqiris press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Canada , Vaccine